RPS6KB1 and non-small cell lung carcinoma: Furthermore, our previous study showed effective inhibition on NSCLC tumorigenicity with a p70S6K‐specific inhibitor, PF‐4708671,27 indicating that p70S6K is a promising target for therapeutic intervention in NSCLC.